ロード中...

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

[Image: see text] RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its less active demethylated pyrazole analogue. Using bioisosteric substitution methods, her...

詳細記述

保存先:
書誌詳細
出版年:J Med Chem
主要な著者: Moccia, Marialuisa, Frett, Brendan, Zhang, Lingtian, Lakkaniga, Naga Rajiv, Briggs, David C., Chauhan, Rakhee, Brescia, Annalisa, Federico, Giorgia, Yan, Wei, Santoro, Massimo, McDonald, Neil Q., Li, Hong-yu, Carlomagno, Francesca
フォーマット: Artigo
言語:Inglês
出版事項: American Chemical Society 2020
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7901654/
https://ncbi.nlm.nih.gov/pubmed/32298114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.9b01336
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!